EFFICIENCY OF HEMOVIGILANCE MODULE TRAININGS GIVEN TO NURSES

EVALUATION OF THE EFFICIENCY OF HEMOVIGILANCE MODULE TRAININGS

The aim of the present study is to determine the effectiveness of hemovigilance module training given to nurses.

Study Overview

• Status: Completed
• Conditions: Nurse's Role; Training Group, Sensitivity
• Intervention / Treatment: Other: Training

Detailed Description

125 nurses from the clinic and intensive care units, who received the most intensive blood transfusion from two different hospitals, were included in the study as the intervention and control groups. The control group was not trained. Only the pretest was administered one week after the posttest. After the pre-test was applied to the nurses in the intervention group, five modules of training, which lasted four hours, were given using interactive methods. Five modules of training were prepared by the researcher. These five modules are the 1st module of training; definition of hemovigilance, its aims, the development of hemovigilance in the world and in Turkey, and legal legislation, Module 2; Donor selection, Blood donation Process, Phlebotomy and Donor reactions, Module 3; blood, blood transfusion, its purpose, properties of blood and blood components, Blood transfusion process, Module 4; acute and delayed transfusion reactions and management, Module 5; It consists of the national hemovigilance system, the organization of the hemovigilance system at the hospital level, Traceability, Trace-back from the Patient to the Donor, and Look-back from the Donor to the Patient. the training was over, the final test was administered. One month later, this test was repeated.

• Study Type: Interventional
• Enrollment (Actual): 125
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Ankara, Turkey
    • Ankara Yıldırım Beyazıt University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

She/He voluntarily agrees to participate in the research, Working as a nurse in the clinic and intensive care unit where blood transfusions are the most, Working for at least 6 months,

Exclusion Criteria:

Nurses working in the emergency and operating rooms, in clinics where blood transfusion is not performed the most, Being a new nurse, On maternity leave and maternity leave, Having an external assignment, Nurses working in the polyclinic,

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention; Five modules of training on hemovigilance were given in 5 hours. A pre-test was applied at the beginning of the training. The final test was done at the end of the training. One month later, the same test was applied again to measure the permanence of the training.	Other: Training; Hemovigilance module training
No Intervention: Control; No training was provided. Only the pretest was administered one week after the posttest.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hemovigilance Information Form	It consists of fifteen questions about hemovigilance and hemovigilance system and definitions.	5 hours or 1 month
Information Form on Blood Transfusion Complications	This section consists of nine questions including transfusion complications.	5 hours or 1 month
Information Form on Blood Transfusion Applications	This section consists of sixteen questions including donor selection, questions about blood components, blood group and safe blood transfusion.	5 hours or 1 month

Collaborators and Investigators

• Sponsor: Ankara Yildirim Beyazıt University

Study record dates

Study Major Dates

• Study Start (Actual): April 25, 2022
• Primary Completion (Actual): May 26, 2022
• Study Completion (Actual): July 8, 2022

Study Registration Dates

• First Submitted: November 15, 2022
• First Submitted That Met QC Criteria: November 15, 2022
• First Posted (Actual): November 23, 2022

Study Record Updates

• Last Update Posted (Actual): November 23, 2022
• Last Update Submitted That Met QC Criteria: November 15, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Hypersensitivity
• Other Study ID Numbers: 2022-38

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No